PharmaVentures

4 Common Mistakes in Partnering

Listen as Fintan Walton, PharmaVentures’ CEO and Founder, discusses the 4 common mistakes being made in partnering and how to avoid them.
 
Fintan provides insight into how to achieve successful deal outcomes by avoiding risks along the clinical, commercial and regulatory pathway, and what fact-based data you need to get your drug to market with the right partner at the right price.
 
About the Interviewee:
 
Fintan Walton is the Founder and CEO of PharmaVentures. He has over 30 years’ experience helping clients achieve success in deal making.
 
Over a period of three decades, he has built it into a global player in supporting transactions for blue chip corporations and emerging innovator corporations. In that time, the firm has delivered more than 1,000 transaction related assignments for companies in 38 countries. 
 
 
About the Presenter:
 
Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.
 
During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

The Importance of Pricing and Market Access in Licensing, Partnering and Early-Stage Development

Listen as Ralph Hughes, PharmaVentures’ Pricing and Market Access expert, talks with Adrian Dawkes about how you can reduce the risk when you want to get your asset onto the market and get ahead of the competition.
 
Understanding incentives, perspectives and funding flows can lead to better pricing and development strategies.
Understanding payer perspectives can help you define market positioning and pricing.
Targeting drug development at payers, as well as the regulators, can ensure adoption.
Payers can become advocates, not blockers, given the right data and narrative.
How combining pricing and market access with valuation work can increase investor confidence.

Medical Device and In Vitro Diagnostic Regulations are changing. How will you be affected?

Listen as Ben Jacoby, Regulatory Expert, talks with Adrian Dawkes about the transition to the new regulations in Europe and UK:
Can existing products continue to be sold?
What will global manufacturers need to do?
What is the impact for companion diagnostics being used alongside drugs in clinical trials?
How is the environment in Great Britain different, and what does this mean for innovators?
What’s the impact for patients?
A rare opportunity to hear from one of the most experienced regulatory advisors in this important space.

The Korean Partnering Opportunity for Western Biopharmaceutical Companies

Listen as JungHyun Eom describes the Korean partnering opportunity for western biopharma companies and her exciting new role establishing PharmaVentures’ office in Seoul to support current and prospective clients in the wider APAC region, serving as the bridge between the innovation in Asia and its commercialisation to the rest of the world. Hosted by Adrian Dawkes.

How to Acquire Companies or Assets Successfully

In this podcast, PharmaVentures’ deal experts discuss the process of helping clients in the life sciences industry acquire or license assets or rights in specific markets or whole companies. Hosted by Adrian Dawkes.

Robust Valuations of Life Science Companies, Assets and Licensing Deals

Listen as Stephen Waterman and Kyriakos Tzafestas describe how PharmaVentures’ real-world experience combines with valuation models, in-depth commercial insight including rigorous pricing, and best quality data sources to value companies, assets and pharma licensing deals to give their clients the confidence to negotiate the most robust and defensible positions in deal making to secure the most impactful financial terms.

Review of 2022: M&A, Licensing and Fundraising

Listen as Fintan Walton, PharmaVentures’ CEO and Founder, reflects on this year’s deal trends in M&A, Licensing and Fundraising, considers the significant macroeconomic events, and offers insight into what impact they may have on the global pharma and biotech industry in 2023. Hosted by Adrian Dawkes.

The Role of CDMOs in a Fast Evolving Manufacturing Landscape

Listen as Jansen Jacob and Steve Garland discuss how the future role of CDMOs in biopharmaceutical manufacturing will be affected by the challenges of cost, new modalities and new innovation; cell and gene therapy (CGT), and personalised medicine. Hosted by Adrian Dawkes.

How Your Pricing and Reimbursement Strategy Affects Your Deal Making Success

Listen as PharmaVentures’ Pricing and Market Access expert, Ralph Hughes, recommends elements of a robust plan to help you achieve the best pricing and market access for your drug, and to give you the increased confidence to strengthen your position during deal making negotiations. Hosted by Adrian Dawkes.